Journal of Shanghai Jiao Tong University (Medical Science) >

2023 , Vol. 43 >Issue 10: 1227 - 1235

DOI: https://doi.org/10.3969/j.issn.1674-8115.2023.10.002

Basic research

Analysis of m6A methylation expression profiles in liver tissue of high-fat diet-induced mouse models of NAFLD

  • Junjun LIU ,
  • Sumei LU ,
  • Bingyang ZHANG ,
  • Yongqing LI ,
  • Wanshan MA
Expand
  • 1.School of Clinical Medicine, Shandong University, Jinan 250014, China
    2.Department of Clinical Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University/Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Laboratory Medicine, Jinan 250014, China
MA Wanshan, E-mail: mwsqianyi@163.com.

Received date: 2023-04-14

  Accepted date: 2023-09-12

  Online published: 2023-10-28

Supported by

Natural Science Foundation of Shandong Province(ZR2021MH187);Shandong Provincial Qianfoshan Hospital, National Natural Science Foundation of China Cultivation Fund(QYPY2020NSFC1004)

Fold

Abstract

Objective ·To detect the differences in m6A methylation modification and gene expression of liver tissue mRNA in high-fat diet-induced mouse models of non-alcoholic fatty liver disease (NAFLD) using microarray technology. Methods ·The NAFLD models were established in 6-8 weeks old male C57BL/6J mice fed with high-fat chow for 16 weeks (high-fat group, n=10). The basal group (n=10) was given 10% fat diet. Hematoxylin-eosin (H-E) staining was used to assess the histopathological changes in liver tissue and to determine the success of the NAFLD models. The changes of mRNA m6A methylation and expression levels in the liver tissues of the two groups were detected by using methylated RNA immunoprecipitation (MeRIP) and microarray expression profiling. Results ·The livers of the mice in the basal group were bright red with few fat deposits, while the livers of the mice in the high-fat group were yellowish with diffuse infiltration and fusion of lipid droplets in the hepatocytes by H-E staining, suggesting that the high-fat diet-induced NAFLD models were successfully constructed. The results of the MeRIP-microarray showed that the m6A methylation levels of 320 genes in the livers of mice in the high-fat group were significantly altered compared with those in the basal group (P<0.05 and fold change>1.5), of which 108 genes were up-regulated and 212 genes were down-regulated. Genes with significant differences in m6A methylation levels between the two groups were intersected with those with differentially expressed mRNAs, and 163 genes were found to have significant differences in both m6A methylation level and mRNA expression level. Conclusion ·The change in m6A modification of liver tissue mRNA in the high-fat diet-induced mouse models of NAFLD is significant and the change is associated with the gene expression of mRNA.

Key words： non-alcoholic fatty liver disease (NAFLD); m6A methylation modification; mRNA; epitranscriptomics

Cite this article

Junjun LIU , Sumei LU , Bingyang ZHANG , Yongqing LI , Wanshan MA . Analysis of m6A methylation expression profiles in liver tissue of high-fat diet-induced mouse models of NAFLD[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023 , 43(10) : 1227 -1235 . DOI: 10.3969/j.issn.1674-8115.2023.10.002

References

1 祥蔚. IL-17A基因敲除减轻LPS诱导的脂肪肝小鼠炎症性肝损伤及其机制研究[D].重庆: 第三军医大学, 2017.
1 XIANG W. IL-17A deficiency alleviates LPS-induced steatotic liver injury in mice and the underlying mechanism[D]. Chongqing: Third Military Medical University of Chinese P.L.A., 2017.
2 ESTES C, ANSTEE Q M, ARIAS-LOSTE M T, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016?2030[J]. J Hepatol, 2018, 69(4): 896-904.
3 CHENG Y, HOU T, PING J, et al. Quantitative succinylome analysis in the liver of non-alcoholic fatty liver disease rat model[J]. Proteome Sci, 2016, 14: 3.
4 XU Z J, SHI J P, YU D R, et al. Evaluating the relationship between metabolic syndrome and liver biopsy-proven non-alcoholic steatohepatitis in China: a multicenter cross-sectional study design[J]. Adv Ther, 2016, 33(11): 2069-2081.
5 YOUNOSSI Z M, KOENIG A B, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84.
6 YOUNOSSI Z M, GOLABI P, DE AVILA L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis[J]. J Hepatol, 2019, 71(4): 793-801.
7 PASCHOS P, PALETAS K. Non alcoholic fatty liver disease and metabolic syndrome[J]. Hippokratia, 2009, 13(1): 9-19.
8 STEFAN N, H?RING H U, CUSI K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies[J]. Lancet Diabetes Endocrinol, 2019, 7(4): 313-324.
9 ALEXANDER M, LOOMIS A K, VAN DER LEI J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts[J]. BMC Med, 2019, 17(1): 95.
10 FRIEDMAN S L, NEUSCHWANDER-TETRI B A, RINELLA M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med, 2018, 24(7): 908-922.
11 DIEHL A M, DAY C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med, 2017, 377(21): 2063-2072.
12 王园园, 蒋建萍. 非酒精性脂肪肝与代谢综合征各组分关系的研究进展[J]. 中国当代医药, 2022, 29(15): 36-39, 43.
12 WANG Y Y, JIANG J P. Research progress of the relationship between nonalcoholic fatty liver disease and components of metabolic syndrome[J]. China Modern Medicine, 2022, 29(15): 36-39, 43.
13 ZHOU J, ZHOU F, WANG W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020, 71(5): 1851-1864.
14 李永清. METTL3介导的CYP2B6 m6A甲基化修饰在非酒精性脂肪性肝病肝细胞胰岛素敏感性中的作用和机制研究[D]. 济南: 山东大学, 2022.
14 LI Y Q. Role and mechanism of METTL3-mediated CYP2B6 m6A methylation modification in insulin sensitivity in hepatocytes with non-alcoholic fatty liver disease[D]. Jinan: Shandong University, 2022.
15 叶棣文, 马万山, 逯素梅. RNAm6A甲基化修饰在代谢综合征中的研究进展[J]. 临床检验杂志, 2022, 40(9): 691-694.
15 YE D W, MA W S, LU S M. Advances in the study of RNA m6A methylation modification in the metabolic syndrome[J].Chinese Journal of Clinical Laboratory Science, 2022,40(9): 691-694.
16 SUMIDA Y, YONEDA M. Current and future pharmacological therapies for NAFLD/NASH[J]. J Gastroenterol, 2018, 53(3): 362-376.
17 陈子扬, 蒲锐, 邓爽, 等. m6A甲基化与代谢性疾病调控[J]. 中国组织工程研究, 2022, 26(20): 3250-3255.
17 CHEN Z Y, PU R, DENG S, et al. N6-methyladenosine methylation and its regulation in metabolic diseases[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(20):3250-3255.
18 PENG Z, GONG Y, WANG X, et al. METTL3-m6A-Rubicon axis inhibits autophagy in nonalcoholic fatty liver disease[J]. Mol Ther, 2022, 30(2): 932-946.
19 韦冷云. Hacd2在脂质代谢中的功能及其作用机制[D]. 无锡: 江南大学, 2022.
19 WEI L Y. Function and mechanism of Hacd2 in lipid metabolism[D]. Wuxi: Jiangnan University, 2022.
20 曾晗. CD36在肝细胞脂质从头合成中的作用及机制研究[D]. 重庆: 重庆医科大学, 2022.
20 ZENG H. The role of CD36 in regulation of hepatocyte de novo lipogenesis[D]. Chongqing: ChongQing Medical University, 2022.
21 仝雪薇, 冶学燕, 刘春燕, 等. 2型糖尿病合并肥胖患者外周血PPARG、CIDEA、ECHDC3、CGN mRNA表达与血脂水平的关系研究[J]. 深圳中西医结合杂志, 2021, 31(6): 4-8, 199.
21 TONG X W, YE X Y, LIU C Y, et al. Relationship between mRNA expression of PPARG, CIDEA, ECHDC3, CGN and lipid levels in peripheral blood of patients with type 2 diabetes mellitus complicated with obesity[J].Shenzhen Journal of Integrated Traditional Chinese and Western Medicine, 2021, 31(6): 4-8, 199.
22 SANS A, BONNAFOUS S, ROUSSEAU D, et al. The differential expression of CIDE family members is associated with NAFLD progression from steatosis to steatohepatitis[J]. Sci Rep, 2019, 9(1): 7501.
23 TANG J, ZHAO X, WEI W, et al. METTL16-mediated translation of CIDEA promotes non-alcoholic fatty liver disease progression via m6A-dependent manner[J]. PeerJ, 2022, 10: e14379.
24 QUIROGA A D, LI L, TR?TZMüLLER M, et al. Deficiency of carboxylesterase 1/esterase-x results in obesity, hepatic steatosis, and hyperlipidemia[J]. Hepatology, 2012, 56(6): 2188-2198.
25 钱胜南. ATP在胰岛素抵抗机制中对线粒体MECR蛋白的影响[D]. 上海: 上海海洋大学, 2020.
25 QIAN S N. Effect of ATP on mitochondrial MECR protein in the mechanism of insulin resistance[D].Shanghai: Shanghai Ocean University, 2020.
26 潘晓燕. FOXO转录因子在饮食诱导的脂肪性肝病中的作用机制研究[D]. 苏州: 苏州大学, 2018.
26 PAN X Y. Study on the mechanisms of action of FOXO transcriptional factors in diet-induced fatty liver disease[D].Suzhou: Soochow University, 2018.
Options
Outlines

/

〈 〉